APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cytomegalovirus(CMV) Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cytomegalovirus(CMV) Treatment Drugs Industry Research Report 2026

26 December 2025128 pages

Choose your research edition.

Industry ResearchCytomegalovirus(CMV) Treatment Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Cytomegalovirus(CMV) Treatment Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Cytomegalovirus(CMV) Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cytomegalovirus(CMV) Treatment Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Cytomegalovirus(CMV) Treatment Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Cytomegalovirus(CMV) Treatment Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cytomegalovirus(CMV) Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cytomegalovirus(CMV) Treatment Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cytomegalovirus(CMV) Treatment Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cytomegalovirus(CMV) Treatment Drugs include Takeda, Novartis, Merck, Roche, Viatris, Moderna, Gilead, Fresenius Kabi and Bausch & Lomb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cytomegalovirus(CMV) Treatment Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cytomegalovirus(CMV) Treatment Drugs Market by Company

Takeda

Novartis

Merck

Roche

Viatris

Moderna

Gilead

Fresenius Kabi

Bausch & Lomb

AlphaVax

Cytomegalovirus(CMV) Treatment Drugs Segment by Type

IV Administration

Oral Administration

Cytomegalovirus(CMV) Treatment Drugs Segment by Application

Hospital

Clinic

Other

Cytomegalovirus(CMV) Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cytomegalovirus(CMV) Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cytomegalovirus(CMV) Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cytomegalovirus(CMV) Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cytomegalovirus(CMV) Treatment Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cytomegalovirus(CMV) Treatment Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cytomegalovirus(CMV) Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cytomegalovirus(CMV) Treatment Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cytomegalovirus(CMV) Treatment Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cytomegalovirus(CMV) Treatment Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cytomegalovirus(CMV) Treatment Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Cytomegalovirus(CMV) Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cytomegalovirus(CMV) Treatment Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cytomegalovirus(CMV) Treatment Drugs, Product Type & Application Table 14. Global Cytomegalovirus(CMV) Treatment Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cytomegalovirus(CMV) Treatment Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Company Information Table 19. Takeda Business Overview Table 20. Takeda Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 22. Takeda Recent Developments Table 23. Novartis Company Information Table 24. Novartis Business Overview Table 25. Novartis Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Novartis Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 27. Novartis Recent Developments Table 28. Merck Company Information Table 29. Merck Business Overview Table 30. Merck Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Merck Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 32. Merck Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Roche Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 37. Roche Recent Developments Table 38. Viatris Company Information Table 39. Viatris Business Overview Table 40. Viatris Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Viatris Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 42. Viatris Recent Developments Table 43. Moderna Company Information Table 44. Moderna Business Overview Table 45. Moderna Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Moderna Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 47. Moderna Recent Developments Table 48. Gilead Company Information Table 49. Gilead Business Overview Table 50. Gilead Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Gilead Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 52. Gilead Recent Developments Table 53. Fresenius Kabi Company Information Table 54. Fresenius Kabi Business Overview Table 55. Fresenius Kabi Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Fresenius Kabi Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 57. Fresenius Kabi Recent Developments Table 58. Bausch & Lomb Company Information Table 59. Bausch & Lomb Business Overview Table 60. Bausch & Lomb Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Bausch & Lomb Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 62. Bausch & Lomb Recent Developments Table 63. AlphaVax Company Information Table 64. AlphaVax Business Overview Table 65. AlphaVax Cytomegalovirus(CMV) Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AlphaVax Cytomegalovirus(CMV) Treatment Drugs Product Portfolio Table 67. AlphaVax Recent Developments Table 68. Global Cytomegalovirus(CMV) Treatment Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Region (2021-2026) & (K Units) Table 70. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Region (2021-2026) Table 71. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Region (2027-2032) & (K Units) Table 72. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Region (2027-2032) Table 73. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Region (2021-2026) Table 75. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Region (2027-2032) Table 77. North America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 79. North America Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 80. North America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Cytomegalovirus(CMV) Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 84. Europe Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 85. Europe Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 89. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 90. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 94. South America Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 95. South America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 99. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 100. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Type (2021-2026) & (K Units) Table 103. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Type (2027-2032) & (K Units) Table 104. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Type (2021-2026) Table 105. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Type (2027-2032) Table 106. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Type (2021-2026) Table 109. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Type (2027-2032) Table 110. Global Cytomegalovirus(CMV) Treatment Drugs Price by Type (2021-2026) & (US$/Unit) Table 111. Global Cytomegalovirus(CMV) Treatment Drugs Price by Type (2027-2032) & (US$/Unit) Table 112. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Application (2021-2026) & (K Units) Table 113. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Application (2027-2032) & (K Units) Table 114. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Application (2021-2026) Table 115. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Application (2027-2032) Table 116. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Application (2021-2026) Table 119. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Application (2027-2032) Table 120. Global Cytomegalovirus(CMV) Treatment Drugs Price by Application (2021-2026) & (US$/Unit) Table 121. Global Cytomegalovirus(CMV) Treatment Drugs Price by Application (2027-2032) & (US$/Unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Cytomegalovirus(CMV) Treatment Drugs Distributors List Table 125. Cytomegalovirus(CMV) Treatment Drugs Customers List Table 126. Cytomegalovirus(CMV) Treatment Drugs Industry Trends Table 127. Cytomegalovirus(CMV) Treatment Drugs Industry Drivers Table 128. Cytomegalovirus(CMV) Treatment Drugs Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cytomegalovirus(CMV) Treatment Drugs Product Image Figure 5. Global Cytomegalovirus(CMV) Treatment Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cytomegalovirus(CMV) Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Cytomegalovirus(CMV) Treatment Drugs Sales (2021-2032) & (K Units) Figure 8. Global Cytomegalovirus(CMV) Treatment Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. IV Administration Product Image Figure 10. Oral Administration Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Other Product Image Figure 14. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Cytomegalovirus(CMV) Treatment Drugs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Cytomegalovirus(CMV) Treatment Drugs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Cytomegalovirus(CMV) Treatment Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Cytomegalovirus(CMV) Treatment Drugs Sales by Region in 2025 Figure 20. Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Region in 2025 Figure 21. North America Cytomegalovirus(CMV) Treatment Drugs Market Size by Country in 2025 Figure 22. North America Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Country (2021-2032) Figure 23. North America Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 24. United States Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Cytomegalovirus(CMV) Treatment Drugs Market Size by Country in 2025 Figure 28. Europe Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Market Size by Country in 2025 Figure 41. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 43. China Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Cytomegalovirus(CMV) Treatment Drugs Market Size by Country in 2025 Figure 52. South America Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Country (2021-2032) Figure 53. South America Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 54. Brazil Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 60. Egypt Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Cytomegalovirus(CMV) Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Type (2021-2032) Figure 66. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Type (2021-2032) Figure 67. Global Cytomegalovirus(CMV) Treatment Drugs Price (US$/Unit) by Type (2021-2032) Figure 68. Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Application (2021-2032) Figure 69. Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Application (2021-2032) Figure 70. Global Cytomegalovirus(CMV) Treatment Drugs Price (US$/Unit) by Application (2021-2032) Figure 71. Cytomegalovirus(CMV) Treatment Drugs Value Chain Figure 72. Cytomegalovirus(CMV) Treatment Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Cytomegalovirus(CMV) Treatment Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • IV Administration
  • Oral Administration
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda
  • Novartis
  • Merck
  • Roche
  • Viatris
  • Moderna
  • Gilead
  • Fresenius Kabi
  • Bausch & Lomb
  • AlphaVax

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cytomegalovirus(CMV) Treatment Drugs Market Size (2021-2032)
  4. 2.2.2 Global Cytomegalovirus(CMV) Treatment Drugs Sales (2021-2032)
  5. 2.2.3 Global Cytomegalovirus(CMV) Treatment Drugs Market Average Price (2021-2032)
  6. 2.3 Cytomegalovirus(CMV) Treatment Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 IV Administration
  9. 2.3.3 Oral Administration
  10. 2.4 Cytomegalovirus(CMV) Treatment Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cytomegalovirus(CMV) Treatment Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cytomegalovirus(CMV) Treatment Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Cytomegalovirus(CMV) Treatment Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cytomegalovirus(CMV) Treatment Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cytomegalovirus(CMV) Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cytomegalovirus(CMV) Treatment Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cytomegalovirus(CMV) Treatment Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Cytomegalovirus(CMV) Treatment Drugs, Established Date
  9. 3.9 Global Cytomegalovirus(CMV) Treatment Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda
  2. 4.1.1 Takeda Company Information
  3. 4.1.2 Takeda Business Overview
  4. 4.1.3 Takeda Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  6. 4.1.5 Takeda Recent Developments
  7. 4.2 Novartis
  8. 4.2.1 Novartis Company Information
  9. 4.2.2 Novartis Business Overview
  10. 4.2.3 Novartis Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novartis Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  12. 4.2.5 Novartis Recent Developments
  13. 4.3 Merck
  14. 4.3.1 Merck Company Information
  15. 4.3.2 Merck Business Overview
  16. 4.3.3 Merck Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  18. 4.3.5 Merck Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 Viatris
  26. 4.5.1 Viatris Company Information
  27. 4.5.2 Viatris Business Overview
  28. 4.5.3 Viatris Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Viatris Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  30. 4.5.5 Viatris Recent Developments
  31. 4.6 Moderna
  32. 4.6.1 Moderna Company Information
  33. 4.6.2 Moderna Business Overview
  34. 4.6.3 Moderna Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Moderna Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  36. 4.6.5 Moderna Recent Developments
  37. 4.7 Gilead
  38. 4.7.1 Gilead Company Information
  39. 4.7.2 Gilead Business Overview
  40. 4.7.3 Gilead Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Gilead Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  42. 4.7.5 Gilead Recent Developments
  43. 4.8 Fresenius Kabi
  44. 4.8.1 Fresenius Kabi Company Information
  45. 4.8.2 Fresenius Kabi Business Overview
  46. 4.8.3 Fresenius Kabi Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Fresenius Kabi Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  48. 4.8.5 Fresenius Kabi Recent Developments
  49. 4.9 Bausch & Lomb
  50. 4.9.1 Bausch & Lomb Company Information
  51. 4.9.2 Bausch & Lomb Business Overview
  52. 4.9.3 Bausch & Lomb Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bausch & Lomb Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  54. 4.9.5 Bausch & Lomb Recent Developments
  55. 4.10 AlphaVax
  56. 4.10.1 AlphaVax Company Information
  57. 4.10.2 AlphaVax Business Overview
  58. 4.10.3 AlphaVax Cytomegalovirus(CMV) Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 AlphaVax Cytomegalovirus(CMV) Treatment Drugs Product Portfolio
  60. 4.10.5 AlphaVax Recent Developments
5 Global Cytomegalovirus(CMV) Treatment Drugs Market Scenario by Region
  1. 5.1 Global Cytomegalovirus(CMV) Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Region: 2027-2032
  5. 5.3 Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Cytomegalovirus(CMV) Treatment Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Cytomegalovirus(CMV) Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Cytomegalovirus(CMV) Treatment Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Cytomegalovirus(CMV) Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Cytomegalovirus(CMV) Treatment Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Cytomegalovirus(CMV) Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Cytomegalovirus(CMV) Treatment Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cytomegalovirus(CMV) Treatment Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Cytomegalovirus(CMV) Treatment Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cytomegalovirus(CMV) Treatment Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Cytomegalovirus(CMV) Treatment Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cytomegalovirus(CMV) Treatment Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cytomegalovirus(CMV) Treatment Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cytomegalovirus(CMV) Treatment Drugs Value Chain Analysis
  2. 8.1.1 Cytomegalovirus(CMV) Treatment Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cytomegalovirus(CMV) Treatment Drugs Production Mode & Process
  5. 8.2 Cytomegalovirus(CMV) Treatment Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cytomegalovirus(CMV) Treatment Drugs Distributors
  8. 8.2.3 Cytomegalovirus(CMV) Treatment Drugs Customers
9 Global Cytomegalovirus(CMV) Treatment Drugs Analyzing Market Dynamics
  1. 9.1 Cytomegalovirus(CMV) Treatment Drugs Industry Trends
  2. 9.2 Cytomegalovirus(CMV) Treatment Drugs Industry Drivers
  3. 9.3 Cytomegalovirus(CMV) Treatment Drugs Industry Opportunities and Challenges
  4. 9.4 Cytomegalovirus(CMV) Treatment Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst